Skip To Main Content
Chuanying Geng on Muck Rack

Chuanying Geng

As seen in: Nature, Wiley Online Library, MDPI, Canadian Journal of Infectious Diseases & Medical Microbiology, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chuanying

Contact Chuanying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine

|
By Ting Shi, Ruicong Xue, Jing Jia, Menghan Liu, Yalan Zhou, Chuanying Geng, Yuan Jian, Ying Tian Verified, Yanru Zhang, Wenjing Li, Lefu Huang, Huixing Zhou, Aijun Liu, Wen Gao, Wenming Chen, Yin Chao Wu, Hong-Hu Zhu, Yun Leng
| Nature Verified
Dear Editor, Acute myeloid leukemia (AML) with the CBFB::MYH11 rearrangement is generally considered a favorable-risk subtype highly responsive to intensive cytarabine-based chemotherapy [1]. However, up to 30% of patients ultimately relapse, driven largely by persistent measurable residual disease (MRD) [1].
Open in Who Shared Issue with article?

Clinical characteristics and prognostic value of circulating plasma ce

|
By Chuanying Geng, Guangzhong Yang, Huixing Zhou, Zhiyao Zhang
| Dove Medical Press
Back to Journals » Journal of Blood Medicine » Volume 16 Authors Geng C , Yang G , Zhou H, Zhang Z, Jian Y, Chen W, Li Y Received 30 December 2024 Accepted for publication 7 May 2025 Published 11 May 2025 Volume 2025:16 Pages 221—231 DOI https://doi.org/10.2147/JBM.S514863 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Martin H Bluth Chuanying Geng, Guangzhong Yang, Huixing Zhou, Zhiyao Zhang, Yuan Jian, Wenming...
Open in Who Shared Issue with article?

Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients

|
By Yuan Jian, Feifei Han, Ying Zhu, Chuanying Geng
| Wiley Online Library Verified
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Venetoclax has demonstrated efficacy in treating acute leukemias and has been recommended as one of the first-line anti-leukemia therapies. Although venetoclax has been suggested to probably possess the ability to penetrate the central nervous system (CNS), current data to elucidate the characteristics of venetoclax in cerebrospinal fluid (CSF), bone marrow (BM), and plasma are still lacking. WHAT QUESTION DID THIS STUDY ADDRESS?
Open in Who Shared Issue with article?
See all 5 licensed articles (6 Total)